Thomas H. Shortt - 14 Jan 2025 Form 4 Insider Report for Vroom, Inc. (VRM)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Mar 2025, 21:07:00 UTC
Prior SEC filing
12 Mar 2024
Next SEC filing
13 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s /Anna-Lisa Corrales, Attorney-in-Fact for Shortt, Thomas H

Key filing fact

Thomas H. Shortt filed Form 4 for Vroom, Inc. (VRM) on 14 Mar 2025.

Key facts

  • This page summarizes Thomas H. Shortt's Form 4 filing for Vroom, Inc. (VRM).
  • 4 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 14 Mar 2025, 21:07.

Change

  • Previous filing in this sequence was filed on 12 Mar 2024.
  • Current net transaction value: +$13,845,548.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRM transaction

Common Stock

Award

Transaction value
$0
Shares
+287,949
Change %
+3436%
Price
$0.000000
Shares after
296,330
Date
12 Mar 2025
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRM transaction Derivative

Warrants (Right to buy)

Award

Transaction value
$13,043
Shares
+214
Change %
Price
$60.95
Shares after
214
Date
14 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
214
Exercise price
$60.95
Footnotes
F3
VRM transaction Derivative

Stock Options (Right to buy)

Award

Transaction value
$7,905,215
Shares
+129,700
Change %
Price
$60.95
Shares after
129,700
Date
12 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
129,700
Exercise price
$60.95
Footnotes
F4
VRM transaction Derivative

Stock Options (Right to buy)

Award

Transaction value
$5,927,290
Shares
+129,700
Change %
Price
$45.70
Shares after
129,700
Date
12 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
129,700
Exercise price
$45.70
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents an award of restricted stock units RSUs, fifty percent of which will vest on January 16, 2029, and fifty percent of which will vest January 17, 2029, in each case subject to the Reporting Person's continued service on such date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F2

The number of shares of common stock in this Form 4 reflect the automatic conversion of the prior common stock at a ratio of 1-for-5 in connection with the Issuer's emergence from bankruptcy on January 14, 2025, the Recapitalization.

Footnote F3

The warrants were issued to stockholders of the Issuer in connection with the Recapitalization. Each Warrant was immediately exercisable upon issuance.

Footnote F4

Twenty-five percent of the shares of common stock that are subject to the option will vest on March 12, 2026 and the remaining Seventy-five percent will vest in three equal installments on each January 14, 2027, January 14, 2028, and January 14, 2029, in each case subject to Reporting Person's continued service on such date.

SEC remarks

All share numbers reported in this Form 4 reflect an automatic conversion of the Common Stock at a ratio of 1-for-5 effectuated by the Amended and Restated Certificate of Incorporation adopted by the Issuer on January 14, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .